The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
Open accessAbstract
Purpose: This systematic review and meta-analysis were performed to assess the efficacy and tolerability of chemotherapy in patients with advanced gastric cancer. Methods: Randomized phase II and III clinical trials on first-line chemotherapy in advanced gastric cancer were identified by electronic searches of Medline, Embase, the Cochrane Controlled Trials Register, and Cancerlit; hand searches of relevant abstract books and reference lists; and contact to experts. Meta-analysis was performed using the fixed-effect model. Overall survival, reported as hazard ratio (HR) with 95% CI, was the primary outcome measure. Results: Analysis of chemotherapy versus best supportive care (HR = 0.39; 95% CI, 0.28 to 0.52) and combination versus single agent, mainly fluorouracil (FU) -based chemotherapy (HR = 0.83; 95% CI = 0.74 to 0.93) showed significant overall survival benefits in favor of chemotherapy and combination chemotherapy, respectively. In addition, comparisons of FU/cisplatin-containing regimens with versus without anthracyclines (HR = 0.77; 95% CI, 0.62 to 0.95) and FU/anthracycline-containing combinations with versus without cisplatin (HR = 0.83; 95% CI, 0.76 to 0.91) both demonstrated a significant survival benefit for the three-drug combination. Comparing irinotecan-containing versus nonirinotecan-containing combinations (mainly FU/cisplatin) resulted in a nonsignificant survival benefit in favor of the irinotecan-containing regimens (HR = 0.88; 95% CI, 0.73 to 1.06), but they have never been compared against a three-drug combination. Conclusion: Best survival results are achieved with three-drug regimens containing FU, an anthracycline, and cisplatin. Among these, regimens including FU as bolus exhibit a higher rate of toxic deaths than regimens using a continuous infusion of FU, such as epirubicin, cisplatin, and continuous-infusion FU.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The pyrimidine analogue 5-fluorouracil (5-FU) is a synthetic analogue of uracil that inhibits thymidylate synthase, limiting the availability of thymidine nucleotides for DNA synthesis (Figure 1b, Figure 2c). 5-FU and the related 5-FU-prodrug capecitabine remain widely used chemotherapies today and are an important treatment for gastrointestinal cancers (Heidelberger et al., 1957; Wagner et al., 2”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Wagner et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research.
Walter, S., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,666
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Chemotherapy for advanced gastric cancer
Wagner, D., Syn, N. L. X., Moehler, M. H., Grothe, W., Yong, W. P., Tai, B., Ho, J., & Unverzagt, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004064.pub4 · Cited by 1,399
Self-citationSepulveda, C. R., Marlin, A., Yoshida, T., & Ullrich, A. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00440-2 · Cited by 1,295
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,132
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Self-citationWebb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A. R., Joffe, J., Hughes, M., Mansi, J., Findlay, M., Hill, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.261 · Cited by 868
Glimelius, B. L. G., Ekström, K., Hoffman, K., Graf, W. D., Sjödén, P., Haglund, U., Svensson, C., Enander, L. K., Linné, T., Sellsröm, H., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008243606668 · Cited by 844
Pyrhönen, S. O., Kuitunen, T., Nyandoto, P., & Kouri, M. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.114 · Cited by 786
Systematic reviews of evaluations of prognostic variables
Altman, D. G. (2001) · BMJ · doi:10.1136/bmj.323.7306.224 · Cited by 756
Research works printed but not linked: 1
- 10.1001/jama.1985.03350380077025 · DOI
Cited by
Sorted by citations
Items 501–600 of 1,000
Kim, Y. S., Sym, S. J., Park, S. H., Park, I., Hong, J., Ahn, H. K., Park, J., Cho, E. K., Lee, W. K., Chung, M., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2334-3 · Cited by 19
“However, combination chemotherapy provides significantly better survival than single agent-chemotherapy or best supportive care [2].”
BackgroundCascinu, S., Galizia, G., Labianca, R., Ferraù, F., Pucci, F., Silva, R. R., Luppi, G., Beretta, G. D., Berardi, R., & Scartozzi, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1424-8 · Cited by 19
“outweighed by a worsening in the toxicity profile in the palliative setting [3].”
BackgroundResultTrarbach, T., Przyborek, M., Schleucher, N., Heeger, S., Lüpfert, C., & Vanhoefer, U. J. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9848-0 · Cited by 19
Management of Gastroesophageal Junction Tumors
Fox, M. P., & van Berkel, V. H. (2012) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.07.011 · Cited by 19
Chen, J., Chao, Y., Bang, Y., Roca, E. L., Chung, H. C., Palazzo, F. G., Kim, Y. H., Myrand, S. P., Mullaney, B. P., Shen, L. J., et al. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833cfbca · Cited by 19
Köş, F. T., Uncu, D., Özdemir, N., Budakoğlu, B., Odabaş, H., Abalı, H., Öksüzoğlu, B. Ç., Aksoy, S., & Zengin, N. (2011) · Chemotherapy · doi:10.1159/000327840 · Cited by 19
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis
Lee, W., Patel, J. H., & Lockhart, A. C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903179286 · Cited by 19
“However, the majority of newly diagnosed patients present with regional or distant metastatic disease where the overall survival is dismal and generally accepted as < 10% [4,5].”
BackgroundLauro, L. D., Giacinti, L., Arena, M. G., Sergi, D., Fattoruso, S. I., Giannarelli, D., & Lopez, M. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-34 · Cited by 19
“However, median time to progression (TTP) is only 4–5 months, with an overall survival (OS) of 7–9 months [3].”
Transcriptome sequencing identifies key pathways and genes involved in gastric adenocarcinoma
Zhang, W., Liu, S., Zhan, H., Yan, Z., & Zhang, G. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9370 · Cited by 19
“Advanced-stage gastric adenocarcinoma has a poor prognosis and the spon-taneous median survival ranges from 3 to 6 months (4).”
Arsenic sulfide induces miR-4665-3p to inhibit gastric cancer cell invasion and migration
Zhang, X., Tan, Z., Kang, T., Zhu, C., & Chen, S. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s209219 · Cited by 19
“And even with comprehensive systematic therapy, the patients with advanced-stage GC are still strongly related to poor prognosis, with the 5-year overall survival rate less than 20%.(3) Although we have already known that Helicobacter pylori infection, as well as many genetic and environmental factors are all crucial…”
BackgroundCapecitabine In the Treatment of Advanced Gastric Cancer
Lee, J., & Kang, Y. (2008) · Future Oncology · doi:10.2217/14796694.4.2.179 · Cited by 19
“Overview of the market Although systemic chemotherapy for AGC is associated with a survival advantage of up to 6 months, as well as improvements in quality of life [11], there has been no worldwide consensus regarding the chemotherapy regimen that should be used as standard first-line treatment.”
BackgroundZhang, X., Xu, J., Liu, H., Yang, L., Liang, J., Xu, N., Bai, Y., Wang, J., & Shen, L. (2014) · Medical Oncology · doi:10.1007/s12032-014-0226-y · Cited by 19
“Systematic chemotherapy can extend overall survival (OS) further than supportive care alone [3].”
BackgroundPous, A. F., Salazar, R., Maurel, J., Tarón, M., Ramírez, J. L., Tabernero, J. M., Gallego, R., Casado, E., Manzano, J. L., Carcereny, E., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0700-3 · Cited by 19
Pietrantonio, F., Biondani, P., de Braud, F., Pellegrinelli, A., Bianchini, G., Perrone, F., Formisano, B., & Bartolomeo, M. D. (2012) · Translational Oncology · doi:10.1596/tlo.12151 · Cited by 19
“There is no standard first-line chemotherapeutic regimen, although cisplatin and fluoropirimidine combination is the backbone of treatment, with or without other agents such as epirubicin or docetaxel [3].”
BackgroundSelenium-binding protein 1 may decrease gastric cellular proliferation and migration
Chenjing, Z., Xu, W., Pan, W., WANG, N., Li, G., Fan, X., Xu, X. M., Shen, S., & Das, U. N. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1850 · Cited by 19
RetractedSurvival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer
Cho, J. H., Lim, J. Y., & Choi, Y. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i41.7407 · Cited by 19
Self-Expandable Metallic Stent Placement in Malignant Gastric Outlet Obstruction
Ye, B.-W., Lee, K., Hsieh, Y., Li, C., Chao, Y., Hou, M., & Lin, H. (2015) · Medicine · doi:10.1097/md.0000000000001208 · Cited by 18
“Second, previous studies showed that the mean survival time of gastric cancer was longer than that of pancreatic cancer and cholangiocarcinoma.(27,29) Thus, shorter stent patency time in pancreatic and cholangiocarcinoma groups might partly be attributed to death which was considered as censor of stent patency in this…”
ResultTumor profiling of gastric and esophageal carcinoma reveal different treatment options
Miura, J. T., Xiu, J., Thomas, J. P., George, B., Carron, B. R., Tsai, S., Johnston, F. M., Turaga, K. K., & Gamblin, T. C. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026479 · Cited by 18
“93).(12) However, up to 50% of patients will not respond to current multi-drug regimens.”
BackgroundSEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma
Rivera, F., Grávalos, C., & García‐Carbonero, R. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0836-9 · Cited by 18
Celio, L., Sternberg, C. N., Labianca, R., Torre, I. L., Amoroso, V., Barone, C. A., Pinotti, G., Cascinu, S., Costanzo, F. D., Cetto, G., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn766 · Cited by 18
“Since accrual of the current study, a meta-analysis has indicated an advantage to three-drug regimens containing 5-FU, an anthracycline, and cisplatin in the management of AGC [22].”
InfluentialLuo, H., Han, L., & Jiang, Y. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.13.5343 · Cited by 18
“Studies showed that treatment with combination chemotherapy improves outcomes compared with singledrug chemotherapy or no chemotherapy in patients with advanced gastric cancer (Ajani, 2006; Wagner et al., 2006).”
BackgroundCalycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells
Zhou, L., Wu, Y., Guo, Y., Li, Y., Li, N., Yang, Y., & Qin, X. (2017) · Cancer Investigation · doi:10.1080/07357907.2016.1278226 · Cited by 18
Doxorubicin combined with Notch1‑targeting siRNA for the treatment of gastric cancer
Zhou, W., Tan, W., Huang, X., & Yu, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.9039 · Cited by 18
“Chemotherapy is one of the first choices for patients with unresectable locally advanced or metastatic GC (3).”
BackgroundChen, Y., Liu, S., QI, M.-H., Zou, X., WU, J., & Zhang, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2766 · Cited by 18
“In recent years, 5‑FU has been widely administered for the treatment of colon cancer (18).”
Anter, A. H., & Abdellatif, R. M. (2013) · Medical Oncology · doi:10.1007/s12032-012-0451-1 · Cited by 18
Novel investigational drugs for gastric cancer
Vecchione, L., Orditura, M., Ciardiello, F., & Vita, F. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902969455 · Cited by 18
“Several cytotoxic agents have shown activity in gastric cancer, and a combination treatment has shown a significant survival benefit over single-agent therapy [13].”
BackgroundAktaş, S. H., AKBULUT, H., YAZICI, O., Zengin, N., Akgun, N., Üstüner, Z., & İçlı, F. (2017) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1509-80 · Cited by 18
Evans, D. L., Miner, T., Akerman, P., Millis, R., Jean, M., Kennedy, T., & Safran, H. P. (2007) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318042d582 · Cited by 18
“A recent meta-analysis has confirmed the benefit of multiagent chemotherapy.(4) Despite these advances, a standardized approach has yet to take hold.”
BackgroundResultLee, H. J., Cho, D. Y., Park, J. C., Bae, S. B., Lee, K. T., Cho, I. S., Han, C. S., Park, S. Y., Yun, H., & Kim, S. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0752-4 · Cited by 18
“Several chemotherapy regimens have been introduced; nevertheless, their survival advantage appears to be marginal and signiWcant treatmentrelated toxicities are usually inevitable [37, 38].”
BackgroundLiu, Y., Ling, Y., Hu, W., Xie, L., Yu, L., Qian, X., Zhang, B., & Liu, B. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep175 · Cited by 18
“5-FU, Oxa and Doc represent the most powerful classes of anticancer agents, and triple combinations containing 5-FU has been wide used in gastric cancer management over the past few years [18].”
BackgroundThe Emerging Role of Immunotherapy in Gastric and Esophageal Adenocarcinoma
Bockorny, B., & Pectasides, E. (2016) · Future Oncology · doi:10.2217/fon-2016-0103 · Cited by 17
Satange, R., Chang, C.-C., Li, L., Lin, S., Neidle, S., & Hou, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad156 · Cited by 17
Transcriptomic subtyping of gastrointestinal malignancies
de Back, T. R., van Hooff, S. R., Sommeijer, D. W., & Vermeulen, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.007 · Cited by 19
Bodoky, G., Scheulen, M. E., Rivera, F., Jassem, J., Carrato, A., Moiseyenko, V. M., Vynnychenko, I. O., Prausová, J., Laethem, J. V., Cascinu, S., et al. (2015) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-014-9680-1 · Cited by 17
Yun, J., Kim, K., Kim, S. T., Kim, J., Kim, J. A., Kong, J. H., Lee, S. H., Won, Y., Sun, J., Lee, J., et al. (2010) · Cancer Research and Treatment · doi:10.4143/crt.2010.42.2.101 · Cited by 17
Baize, N., Abakar-Mahamat, A., Mounier, N., Berthier, F., & Caroli‐Bosc, F. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0903-7 · Cited by 17
“Recently, a meta-analysis of randomized controlled trials in patients with advanced cancers conWrmed these data and in addition demonstrated that combination chemotherapy is associated with a survival beneWt comparing single-agent chemotherapy [ 8 ].”
BackgroundMethodJin, J., Lv, H., Wu, J., Li, D., Chen, K., Zhang, F., Han, J., Feng, J., Zhang, N., Yu, H., et al. (2017) · Medical Science Monitor · doi:10.12659/msm.903134 · Cited by 17
“The 5-fluorouracil (5-FU) based chemotherapy is a standard treatment for patients with advanced GC [6].”
BackgroundThe prognostic significance of inflammation-based markers in patients with recurrent gastric cancer
Migita, K., Matsumoto, S., Wakatsuki, K., Ito, M., Kunishige, T., Nakade, H., Kitano, M., Nakatani, M., & Sho, M. (2017) · Surgery Today · doi:10.1007/s00595-017-1582-y · Cited by 17
“However, few reports have investigated the role of inflammation-based markers in patients with RGC [15].”
InfluentialNamikawa, T., Ishida, N., Tsuda, S., Fujisawa, K., Munekage, E., Iwabu, J., Munekage, M., Uemura, S., Tsujii, S., Maeda, H., et al. (2018) · Surgical Case Reports · doi:10.1186/s40792-018-0479-3 · Cited by 17
Current trends in gastric cancer treatment in Europe
Kamiya, S., Rouvelas, I., Lindblad, M., & Nilsson, M. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2017.76 · Cited by 17
“This study suggested that Western adjunct treatment should shift to 5-FU: fluorouracil; BSC: best supportive care; CRT: chemoradiotherapy; CT: chemotherapy; DCF: docetaxel/cisplatin/fluorouracil; DFS: disease free survival; ECF: epirubicin/cisplatin/fluorouracil; ECX: epirubicin/cisplatin/capecitabine; EOF: epirubicin…”
BackgroundInfluentialHuang, H., Zhang, L., Chen, D., Yu, X., He, X., Liu, M., & Chen, P. (2018) · Journal of Cancer · doi:10.7150/jca.26637 · Cited by 17
“As treatment plans are becoming more individualized for each patient, it is important to assess disease progression in a timely manner and accurately evaluate the prognosis[4].”
BackgroundRANKL/RANK promotes the migration of gastric cancer cells by interacting with EGFR
Wan, X., Song, Y., Fang, H., Xu, L., Che, X., Wang, S., Zhang, X., Zhang, L., Li, C., Fan, Y., et al. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0249-2 · Cited by 17
“In recent years, chemokines and their receptor-signaling pathways have been reported to have major roles in the metastasis of cancer cells [3].”
BackgroundMatus, M. F., Malola, S., & Häkkinen, H. (2021) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.1c00008 · Cited by 17
“40,41 Also, di ff erent inhibitors of signaling pathways that have been identi fi ed as the molecular mechanism underlying cell survival under cytotoxic pressure in GC were included: 42 − 45 linifanib (LIN; VEGF inhibitor), 46 tanespimycin (TAN; HIF inhibitor), 43 taselisib (TAS; PI3K inhibitor), 47…”
High levels of platelet/lymphocyte ratio are associated with metastatic gastric cancer.
Çetinkünar, S., Güzel, H., Gökce, İ. E., Erdem, H., Gülkan, S., Aktimur, R., Küçük, B., İmamoğlu, İ., & Kargıcı, H. (2015) · PubMed · Cited by 17
Efficacy of S-1vscapecitabine for the treatment of gastric cancer: A meta-analysis
He, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i14.4358 · Cited by 17
Brell, J. M., Krishnamurthi, S., Javle, M. M., Saltzman, J. N., WOLLNER, I. S., Pelley, R. J., Dowlati, A., Kantharaj, B. N., SCHLUCHTER, M. D., Rath, L., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0807-6 · Cited by 17
“The incidence of stomach/GEJ adenocarcinoma has remained essentially stable over the past few years, except for the known increase in GEJ and distal esophagus adenocarcinomas in the United States, starting in approximately 1975 [5, 25 ].”
BackgroundInfluentialClinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
Park, J. S., Rha, S. Y., Chung, H. C., Jung, M., Kim, K. H., Jun, H. J., Kim, H., An, J. Y., Kim, H., Cheong, J., et al. (2014) · Oncology · doi:10.1159/000368555 · Cited by 17
Rivera, F., Massutí, B., Salcedo, M., Sastre, J., Martínez-Galán, J., Valladares‐Ayerbes, M., Serrano, R., de Paredes, M. G., Manzano, J. L., Galan, M., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2641-3 · Cited by 17
Shi, Y., Yu, P.-W., Zeng, D.-Z., Qian, F., Lei, X., Zhao, Y., Tang, B., Hao, Y., Luo, H.-X., Chen, J., et al. (2014) · FEBS Journal · doi:10.1111/febs.12923 · Cited by 17
Secondary signet-ring cell adenocarcinoma of urinary bladder from a gastric primary
Sharma, P., Vijay, M. K., Das, R., & Chatterjee, U. (2011) · Urology Annals · doi:10.4103/0974-7796.82177 · Cited by 17
Shen, X., Wang, J., Yan, X., Ren, X., Wang, F., Chen, X., & Xu, Y. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3047-1 · Cited by 17
Emerging Role of Capecitabine in Gastric Cancer
Camella, P., Franco, L., Casaretti, R., de Portu, S., & Menditto, E. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.3.318 · Cited by 17
“52) in favor of the chemotherapy arms, which translates to a benefit in weighted mean average survival of approximately 6 months in comparison with patients treated with best supportive care alone.(6) Fluorouracil”
BackgroundResultRyu, M., & Kang, Y. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.149 · Cited by 16
Chemotherapy beyond second-line in advanced gastric cancer
Kim, S. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i29.8811 · Cited by 16
Kim, J. H., Lee, H. H., Seo, H. S., Jung, Y. J., & Park, C. H. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.05.023 · Cited by 16
Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls
Epistola, R., & Chao, J. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.01.10 · Cited by 16
Cha, B. H., Lee, S. H., Kim, J. E., Yoo, J. Y., Park, Y. S., Kim, J., Jeong, S., Kim, N., Lee, D. H., & Hwang, J. (2012) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2012.01590.x · Cited by 16
Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future
Mulder, K. E., Koski, S. L., Scarfe, A. G., Chu, Q. S.-C., King, K. M., & Spratlin, J. L. (2010) · Oncotarget · doi:10.18632/oncotarget.187 · Cited by 16
“Although there is no single internationally accepted standard of care regimen, the best survival rates are achieved with three drug combinations compared to doublet therapy [19].”
BackgroundPaclitaxel-based regimens as first-line treatment in advanced gastric cancer
Guo, Z., Wang, X., Lin, R., Chen, L., Fan, N., Chen, Y., Lin, J., & Yu, J. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000169 · Cited by 16
Zhou, Y., Wei, L., Zhang, H., Dai, Q., Li, Z., Yu, B., Guo, Q., & Lu, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25118 · Cited by 17
“, 2004], the prognosis of advanced and unresectable GC remains quite poor [Wagner et al., 2006; Ott et al., 2011; Hayakawa et al., 2012].”
BackgroundRetractedRandomized Clinical Trials in Esophageal Carcinoma
Barnett, S. A., & Rizk, N. P. (2009) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2009.09.007 · Cited by 16
Pharmacogenetics and Stomach Cancer: An Update
Toffoli, G., & Cecchin, E. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.5.497 · Cited by 16
“However, at present, appropriate chemotherapy treatment for metastatic GC should primarily be guided by the principles of palliative care [7].”
BackgroundWöll, E., Greil, R., Eisterer, W., Bechter, O. E., Fridrik, M., Grünberger, B., Zabernigg, A. F., Mayrbäurl, B., Russ, G., Dlaska, M., et al. (2011) · PubMed · Cited by 16
Lee, K., Lee, J. H., Kim, J. W., Kim, J.-W., Ahn, S., & Kim, J. H. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-015-2075-2 · Cited by 16
“In patients with metastatic GC (MGC), palliative chemotherapy has been proven to play an important role in improving survival and quality of life (Wagner et al. 2006; Wohrer et al. 2004).”
BackgroundResultInfluentialNeoadjuvant therapy for gastroesophageal adenocarcinoma
Samalin, E., & Ychou, M. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i3.284 · Cited by 16
Erdem, G. U., Bozkaya, Y., Özdemir, N., Demirci, N. S., Yazıcı, O., & Zengin, N. (2017) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2017.2258 · Cited by 16
“In previous studies, when used as a first-line option, combination regimens were reported to be better than single-agent treatments [2,3].”
BackgroundLi, L., Yang, D., Cui, D., Li, Y., Nie, Z., Wang, J., & Liang, L. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4231 · Cited by 16
“Unfortunately, the majority of patients are diagnosed at the advanced stages of the disease, when chemotherapy is regarded as an important component of multimodal treatment (33).”
miR‐618 Suppresses Metastasis in Gastric Cancer by Downregulating the Expression of TGF‐β2
Shi, J., Gong, L., Chen, L., Luo, J., Song, G., Xu, J., Lv, Z., Tao, H., Xia, Y., & Ye, Z. (2019) · The Anatomical Record · doi:10.1002/ar.24083 · Cited by 16
“Unfortunately, most GC patients are diagnosed at an advanced stage and the 5-year overall survival is no more than 20%, even with the combined application of surgical and chemotherapy treatment (Wagner et al., 2006).”
BackgroundTakimoto, R., Kamigaki, T., Okada, S., Matsuda, E., Ibe, H., Oguma, E., Naitoh, K., Makita, K., & Goto, S. (2017) · Anticancer Research · doi:10.21873/anticanres.11778 · Cited by 16
Pourghasemian, M., Mehr, A. D., Molaei, M., & Habibzadeh, A. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.8.2337 · Cited by 16
“outcomes have not been satisfactory, chemotherapy has been associated with higher survival and better quality of life compared to supportive treatment (Casaretto et al., 2006; Glimelius et al., 1997; Wagner et al., 2006; Wagner et al., 2010).”
BackgroundBoku, N., Muro, K., Machida, N., Hashigaki, S., Kimura, N., Suzuki, M., Lechuga, M., & Miyata, Y. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9948-5 · Cited by 16
“Despite recent advances in the treatment for gastric cancer [6], a standard chemotherapy regimen has not been established for recurrent or unresectable advanced gastric cancer; combination chemotherapy is associated with significant survival and quality of life advantages, compared with best supportive care [7, 8].”
BackgroundComella, P., Lorusso, V., Maiorino, L., Casaretti, R., Cannone, M., Massidda, B., Putzu, C., Leo, S., Roselli, M., Mancarella, S., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0938-4 · Cited by 16
“A recent meta-analysis showed that combination regimens achieve better survival outcomes than Xuorouracil monotherapy, and that regimens containing Xuorouracil, anthracyclines and cisplatin are the most eVective [3].”
BackgroundHe, B., Zhang, H., Xiong, S.-P., Lu, S., Wan, Y., & Song, R. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.8.3111 · Cited by 16
“Chemotherapy is one of the main treatments for advanced gastric cancer and, to a certain extent, can prolong patient survival and improve quality of life (Wagner et al., 2006).”
BackgroundPinto, L. C., Moreira-Nunes, C. A., Soares, B. M., Burbano, R. M. R., de Lemos, J. A. R., & Montenegro, R. C. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.06.007 · Cited by 16
Raab, R., Sparano, J. A., Ocean, A. J., Christos, P. J., Ramirez, M., Vinciguerra, V. P., & Kaubisch, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181a31ad0 · Cited by 16
“Because of the limited activity of single-agent chemotherapy, combination regimens are commonly used, which generally include 5-fluorouracil (5-FU) and cisplatin; response occurs in about 20%, and median survival is approximately 7 to 10 months.(3) New strategies are needed to enhance the activity of cytotoxic therapy.”
BackgroundLauro, L. D., Nunziata, C., Arena, M. G., Foggi, P., Sperduti, I., & López, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603917 · Cited by 16
“Classical cisplatin-based regimens obtain responses in 20–40% of the patients with metastatic gastric or GEJ cancer, a median TTP of about 4 months and a median survival of 8 –9 months (Wagner et al, 2006).”
Yao, A., Wang, Y., Peng, X., Ye, R., Wang, Q.-L., Qi, Y., & Zhou, F. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1758-4 · Cited by 15
Bai, Y., Xu, Y., & Wu, B. (2017) · Gastroenterology Research and Practice · doi:10.1155/2017/2816737 · Cited by 15
“Systemic chemotherapy based on the combination of fluoropyrimidine and platinum is widely accepted as a palliative treatment that substantially improves overall survival and quality of life compared with singleagent chemotherapy or best supportive care [3].”
BackgroundVisa, L., Jiménez‐Fonseca, P., Asensio, E., Hernández, R., Custodio, A., Garrido, M., Viúdez, A., Buxó, E., Echavarria, I., Cano, J. M., et al. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.11.008 · Cited by 15
“However, older participants are underrepresented in most clinical trials; the median age of AGC clinical trial participants is between 54 and 65 years(5).”
BackgroundMotamedi, Z., Amini, S. A., Raeisi, E., LEMOIGNE, Y., & Heidarian, E. (2019) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2019.69335 · Cited by 16
Yang, X., & Liu, R. (2022) · Bioengineered · doi:10.1080/21655979.2022.2034565 · Cited by 15
“Gastric cancer (GC) is a digestive tract malignant tumor[1], [2] and has become one of the major diseases seriously endangering people’s health due to its annually increased incidence and decreased onset age [3].”
BackgroundPerioperative Tailored Treatments for Gastric Cancer: Times Are Changing
Lavacchi, D., Fancelli, S., Buttitta, E., Vannini, G., Guidolin, A., Winchler, C., Caliman, E., Vannini, A., Giommoni, E., Brugia, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054877 · Cited by 16
Lord, S., Hall, P. S., McShane, P., Brown, J. M., & Seymour, M. (2010) · Clinical Oncology · doi:10.1016/j.clon.2009.12.001 · Cited by 15
Shen, J., Wang, H., Wei, J., Yu, L., Xie, L., Qian, X., Zou, Z., Liu, B., & Guan, W. (2012) · International Journal of Cancer · doi:10.1002/ijc.27530 · Cited by 15
Eren, O. Ö., Öztürk, M. A., Sönmez, Ö., & Oyan, B. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000156 · Cited by 15
“Nevertheless, palliative chemotherapy is superior to best supportive care for improving OS and quality of life.(6,7) A small percentage of patients with metastatic disease may benefit from targeted agent trastuzumab.”
BackgroundCao, Y., Qu, J., Li, C., Yang, D., Hou, K., Zheng, H., Liu, Y., & Qu, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3232-6 · Cited by 15
Targeted therapies in the treatment of gastric cancer
Ngeow, J. Y. Y., Tan, I. B., & Choo, S. P. (2011) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2011.01407.x · Cited by 15
Hu, X., Huang, Z., Liao, Z., He, C., & Fang, X. (2014) · PubMed Central · Cited by 15
Capecitabine for the treatment of gastric cancer
Kim, T., Oh, D., & Bang, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1096774 · Cited by 15
“Chemotherapy improves survival and quality of life in patients with advanced gastric cancer (AGC) compared with the best supportive care [4].”
BackgroundZhao, T., Xu, Z., Gu, D., Wu, P., Huo, X., Wei, X., Tang, Y., Gong, W., He, M., & Chen, J. (2016) · Scientific Reports · doi:10.1038/srep28019 · Cited by 15
Kim, M., Kong, S., Nam, B., Kim, S., Park, Y., & Park, S. R. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000320 · Cited by 15
Tang, C., Yu, S. L., Jiang, H., Li, W., Xu, X., Cheng, X., Peng, K., Chen, E., Cui, Y., & Liu, T. (2018) · Journal of Cancer · doi:10.7150/jca.23391 · Cited by 15
“It is widely accepted that chemotherapy is an indispensable part of MDT, since both palliative chemotherapy for advanced disease and perioperative chemotherapy have been proved to improve survival and quality of life in patients with GC [3] and 5-fluorouracil (5-Fu) based regimens are most generally used in this area.”
BackgroundKim, H., Ro, S. M., Yang, J. H., Jeong, J. W., Lee, J. E., Roh, S. Y., & Kim, I.-H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.293 · Cited by 15
“However, chemotherapy remains the mainstream first-line treatment for mGC, and the overall survival (OS) of mGC averages less than 1 year [2,4,6-9].”
BackgroundChou, W., Chang, C., Liu, K.-H., Hsu, J., Hsu, H., Shen, W., Hung, Y., & Chen, J. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-287 · Cited by 15
“Gastric cancer is relatively sensitive to chemotherapy in its advanced stages [6,7]; thus, adjuvant chemotherapy is often administered to patients with gastric cancer after curative surgery to prevent tumor recurrence and prolong survival time.”
BackgroundOh, S. C., Sur, H. Y., Sung, H. J., Choi, I., Park, S. S., Seo, J. H., Jeen, Y. T., Chun, H. J., Shin, S. W., Mok, Y. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603752 · Cited by 15
“In recent meta-analysis of chemotherapies used to treat advanced gastric cancer, a comparison between irinotecan-containing versus nonirinotecan-containing combinations (mainly 5-FU/cisplatin) showed a non-survival benefit in favour of irinotecan-containing regimens (HR¼ 0.88) (Wagner et al, 2006).”
InfluentialManagement of gastric cancer: East vs west
Park, S. R. (2015) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.005 · Cited by 14
Labots, M., Buffart, T. E., Haan, J. C., van Grieken, N. C. T., Tijssen, M., van de Velde, C. J. �., Grabsch, H. I., Ylstra, B., Carvalho, B. G., Fijneman, R. J. A., et al. (2013) · Cellular Oncology · doi:10.1007/s13402-013-0162-4 · Cited by 14
“The current firstline systemic treatment for locally advanced or metastatic disease is based on a combination of fluoropyrimidine and platinum chemotherapy regimens [3, 4].”
BackgroundQi, W., Shen, Z., Lin, F., Sun, Y., Min, D., Tang, L., He, A., & Yao, Y. (2012) · International Journal of Cancer · doi:10.1002/ijc.27775 · Cited by 14
“Compared to the studies of Wagner et al.6 and Wang et al.,21 the number of eligible trials in this study was the most.”
BackgroundResultInfluentialLim, D. H., Park, S. H., Park, K. W., Kang, J. H., Oh, S. Y., Hwang, I. G., Kwon, J. M., Lee, S., Lee, H.-Y., Kim, H. S., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-583 · Cited by 14
“A meta-analysis showed a difference in OS of approximately 2 months in favor of the anthracycline-containing triplets versus doublets [13].”
BackgroundYoon, Y., Im, S., Min, A., Kim, H., Hur, H.-S., Lee, K.-H., Han, S., Song, S., Oh, D. Y., Kim, T., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.019 · Cited by 14
Metadata
- Authors
- Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E.
- Affiliations
- From the First Department of Medicine, Coordinating Centre for Clinical Trials, Department of Medicine IV, and Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany; and Mayo Clinic College of Medicine, Rochester, MN
- Mayo Clinic (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2006-06-20
- Volume
- 24
- Issue
- 18
- Pages
- 2903-2909
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145390243
- Cited by
- 1,171
- References
- 51
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 26 · 2023: 28 · 2022: 34 · 2021: 64 · 2020: 55 · 2019: 54 · 2018: 69 · 2017: 89 · 2016: 72 · 2015: 84 · 2014: 105 · 2013: 92 · 2012: 77
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Society of Clinical Oncology
- Bundesministerium für Bildung und Forschung (01GH0105)
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- advanced gastric cancer, first-line chemotherapy, 5-fluorouracil, cisplatin, anthracyclines, irinotecan, combination chemotherapy, overall survival, best supportive care, epirubicin, chemotherapy toxicity
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Humans, Stomach Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
